← Russell 3000 cross-section

PCRX Pacira BioSciences, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$1.0bn
Revenue TTM
$746m
Net income TTM
$15m
Free cash flow
$180m
Composite score
48.9
Sector rank
#1995

Valuation

P / E
70.5
EV / EBITDA
10.9
EV / sales
1.5
FCF yield
17.39%
Earnings yield vs 10-yr
-3.32pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
2.0%
EBITDA margin
14.1%
ROE
2.2%
ROIC
2.5%
Revenue growth
5.7%

Insider activity, last 90 days

Net open-market
$-0.44m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Recent Highlights • In June 2026, we entered into a Stock and Asset Purchase Agreement with Zimmer to divest iovera° for up to $140.0 million, including an upfront payment of $70.0 million and potential contingent consideration of up to an additional $70.0 million in the aggregate, payable upon the achievement of revenue-based milestones up to and through the period ending December 31, 2031 (the “Transaction”). The following table provides information regarding our revenues during the periods indicated, including percent changes (dollar amounts in thousands): EXPAREL revenue increased 3% and 4% in the three and six months ended June 30, 2026 versus 2025, respectively. …Pacira BioSciences, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →